Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 AUD | -16.67% | 0.00% | 0.00% |
05/03 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
27/02 | Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | 3.29M 2.16M 181M | Sales 2023 | 4.1M 2.69M 225M | Capitalization | 25.69M 16.86M 1.41B |
---|---|---|---|---|---|
Net income 2022 | -2M -1.31M -110M | Net income 2023 | -1M -657K -54.85M | EV / Sales 2022 | 15 x |
Net cash position 2022 | 8.47M 5.56M 465M | Net cash position 2023 | 4.08M 2.68M 224M | EV / Sales 2023 | 5.26 x |
P/E ratio 2022 |
-22.6
x | P/E ratio 2023 |
-13.4
x | Employees | 4 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 50.95% |
1 day | -16.67% | ||
Current month | -16.67% | ||
1 month | -16.67% | ||
3 months | +25.00% | ||
6 months | -16.67% |
Managers | Title | Age | Since |
---|---|---|---|
Thian Chew
CEO | Chief Executive Officer | - | 01/17/01 |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | 13/20/13 |
Brendon Lau
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 22/20/22 | |
Thian Chew
CEO | Chief Executive Officer | - | 01/17/01 |
Alan Yamashita
BRD | Director/Board Member | 74 | 12/19/12 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 0.005 | -16.67% | 11 819 |
24/24/24 | 0.006 | 0.00% | 50,000 |
23/24/23 | 0.006 | +20.00% | 304,457 |
22/24/22 | 0.005 | -16.67% | 600,080 |
Delayed Quote Australian S.E., April 29, 2024 at 11:12 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
0.00% | 25.14M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IVX Stock